Business
Almirall Q1 2025 Results
BARCELONA, Spain, May 12, 2025--Almirall, S.A. (ALM) a global pharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2025. Almirall continued to deliver strong sales growth in the first quarter of the year - in line with expectations and with the longer-term growth trajectory set out by the company. Almirall’s performance continues to be driven by its dermatology business in Europe, and by delivering advanced therapies and a broad portfolio of rel
About this update from Almirall Sa
[{"type":"image","alt":"Almirall HQ in Barcelona","displaySize":"","headline":null,"caption":"Almirall HQ in Barcelona","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":469,"url":"https://media.zenfs.com/en/business-wire.com/b873c28a3addab35028d6ff9fa8663db"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l3KXZCzOT398.8MMZyco2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTkzODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b873c28a3addab35028d6ff9fa8663db","width":480,"height":469}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/f1a1e619a27c959b79eff9464cdbc1e6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DwrQC5w.O_RGbhfU7rtJvA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f1a1e619a27c959b79eff9464cdbc1e6","width":480,"height":210}}},{"type":"text","content":"Almirall delivers a strong start to 2025: growing Q1 overall sales by 15%, and 23.4% in its European Dermatology business YoY, aligned with the company’s sustained growth trajectory","length":181,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued strong growth trajectory with 15% Net Sales increase to a total of €284.6 MM with key products delivering high double-digit YoY growth and general medicines business aided by Q1 2025 out-licensing transaction.","length":219,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"EBITDA increase of 35.0% YoY in line with expectations to a total of €70.9 MM driven by continued strong operational execution including out-licensing income realized in Q1 2025.","length":178,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Performance was driven by the biologics portfolio, with Ilumetri® showing 12.7% increase in sales vs Q1 2024 (total of €55.1 MM), and Ebglyss® delivering €19.4 MM quarterly sales - mainly achieved by the continued positive launch dynamics in Germany and growing contributions from recent launched countries.","length":307,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The broad dermatology product portfolio continues its sustained growth including performance in line with expecta...